Rosen Law Seeks Lead Plaintiff in ImmunityBio Securities Suit After FDA Ad Warning

Overview

• Rosen Law Firm says it filed a class action and is urging ImmunityBio investors to move for lead-plaintiff status by May 26, 2026.
• The suit targets purchases made between January 19, 2026 and March 24, 2026, which the firm identifies as the class period.
• The litigation follows an FDA letter finding a TV ad and a January podcast about Anktiva were false or misleading about efficacy and use.
• Coverage of the FDA letter triggered a drop of more than 21% in ImmunityBio’s share price, wiping out nearly $2 billion in market value.
• Allegations include claims that Executive Chairman Patrick Soon‑Shiong overstated Anktiva’s capabilities, and no class has been certified as firms solicit investors on a contingency basis.